SCHEMBL2134012

SCHEMBL2134012

Cc1cc(-c2cccc(C(F)(F)F)c2)ccc1C(=O)N1CC(N[C@H]2CCN(C(=O)c3nccs3)C2)C1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 8/20 0.47
CYP3A4 P08684 3/20 0.44
RBP4 P02753 1/20 0.43
CYP2C9 P11712 1/20 0.42
SLC6A7 Q99884 1/20 0.41
GAA P10253 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
KCNH2 Q12809 4/20 0.39
SPR P35270 1/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
MGLL Q99685 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2130799 0.91 CCR2 (0.47) CCR2CYP3A4RBP4CYP2C9SLC6A7
SCHEMBL2130865 0.90 SLC6A7 (0.52) CCR2CYP3A4RBP4CYP2C9SLC6A7
SCHEMBL2131690 0.85 CYP3A4 (0.43) CCR2CYP3A4RBP4CYP2C9SLC6A7
SCHEMBL912740 0.85 MGLL (0.51) SLC6A7ABL1BCRMGLL
SCHEMBL912403 0.85 MGLL (0.51) SLC6A7ABL1BCRMGLL
SCHEMBL2132639 0.84 CCR2 (0.47) CCR2SLC6A7ABL1BCRMGLL
SCHEMBL2132107 0.84 CCR2 (0.43) CCR2CYP3A4RBP4CYP2C9SLC6A7
SCHEMBL2129688 0.84 CCR2 (0.43) CCR2CYP3A4RBP4CYP2C9SLC6A7
SCHEMBL2732825 0.84 CCR2 (0.43) CCR2CYP3A4RBP4CYP2C9SLC6A7
SCHEMBL2131757 0.82 MGLL (0.44) CCR2CYP3A4RBP4CYP2C9SLC6A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 US claimed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 US claimed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US claimed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 US claimed
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 US disclosed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 US disclosed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 US disclosed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL CCR2 2148/4885CYP3A4 2393/4885RBP4 3161/4885
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL CCR2 2148/4885CYP3A4 2393/4885RBP4 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.